The usual suspects have done a fine job of turning the CRISPR patent landscape into a minefield for companies trying to figure out what intellectual property they need to make their hoped-for therapies, but an unusual suspect is about to mix things up even more.

The MilliporeSigma subsidiary of Germany-based pharmaceutical company Merck KGaA will soon receive a patent on an invention that increases CRISPR’s efficiency and decreases its off-target effects, according to documents posted this month by the U.S. Patent and Trademark Office. Both attributes could be extremely useful to would-be developers of treatments based on the genome-editing tool.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy